Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

BACKGROUND: In the EMBRACA phase III study (NCT01945775), talazoparib was associated with a significantly prolonged progression‐free survival (PFS) compared with physician's choice of chemotherapy (PCT) in germline BRCA1/2‐mutated HER2‐negative advanced breast cancer (ABC). Herein, the safety p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurvitz, Sara A., Gonçalves, Anthony, Rugo, Hope S., Lee, Kyung‐Hun, Fehrenbacher, Louis, Mina, Lida A., Diab, Sami, Blum, Joanne L., Chakrabarti, Jayeta, Elmeliegy, Mohamed, DeAnnuntis, Liza, Gauthier, Eric, Czibere, Akos, Tudor, Iulia Cristina, Quek, Ruben G.W., Litton, Jennifer K., Ettl, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066700/
https://www.ncbi.nlm.nih.gov/pubmed/32162822
http://dx.doi.org/10.1634/theoncologist.2019-0493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066700/
https://www.ncbi.nlm.nih.gov/pubmed/32162822
http://dx.doi.org/10.1634/theoncologist.2019-0493

Ejemplares similares